Toronto, Ontario–(Newsfile Corp. – November 9, 2021) – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on non-hallucinogenic, psychedelic-based therapies for use in the treatment of mental health, will be presenting at Wonderland Miami Conference by Microdose on Monday, November 8th, on the topic of accessible psilocybin-based drugs.
Judy Blumstock, Founder and CEO of Diamond, will be speaking as part of the fifth panel, Microdosing: Fact or Fiction? which starts at 2.00 p.m. EST. Ms. Blumstock will be discussing the possibility of opening broader access to psychedelic treatment with low-dose, affordable, non-impairing psychedelics that can be taken at home.
“The goal is to positively impact the current global mental health crisis. Our first clinical trial program is focused on accessible psilocybin-based drugs without undesired psychoactive effects. Through the elimination of unwanted effects, there is potential for broad administration of treatment,” says Judy Blumstock, CEO of Diamond Therapeutics.
Get tickets https://microdose.buzz/wonderland-miami/
About Diamond Therapeutics
Diamond Therapeutics is a drug development company based in Toronto, Ontario. Our mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. Diamond is focused on sub-perceptual, non-hallucinogenic treatments that hold potential for use across a broad patient cohort -maximizing the positive impact better drugs can have on global mental health. To learn more about Diamond, visit www.diamondthera.com.
Cautionary Statements Regarding Forward-Looking Information
This news release includes certain “forward-looking information” under applicable Canadian securities legislation. Forward-looking information includes statements other than statements of historical fact that can be identified by phrases such as “expects”, “anticipates”, “intends”, “aims”, “plans” and “believes”, and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements in this news release include, but are not limited to, the potential effects of low dose psilocybin and other psychedelic treatments, the potential use in treating mental health conditions and the timing and completion of Diamond’s clinical programs and trials. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive applicable regulatory approvals; that factors may occur which impede Diamond’s future business plans; the results of continued development, marketing and sales; and other factors beyond the control of Diamond. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Diamond disclaims any intention or obligation to update or revise any forward-looking information in this news release, whether as a result of new information, future events or otherwise, except as required by law.
Wonderland: Miami will offer the industry a unique in-person convergence of business, science, music, and emerging technologies. The event is a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business. It will also act as a launching pad for innovative content connected to the psychedelic medicine space, providing compelling entertainment and collaboration opportunities for attendees.
About Microdose Psychedelics Insights
Microdose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, we distribute and create the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102408